Tech Company Financing Transactions

Dicerna Pharmaceuticals Funding Round

On 11/14/2007, Dicerna Pharmaceuticals secured $13 million in Series A funding from Oxford Bioscience Partners and Skyline Ventures.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A

Oxford Bioscience Partners (Lead Investor) (Douglas Fambrough)

Skyline Ventures (Lead Investor) (Stephen Hoffman)

Proceeds Purpose
Dicerna will create novel drugs that take advantage of the same cellularmachinery responsible for the well-known phenomenon of RNA interference(RNAi) but with a key difference. In contrast to existing companies, Dicerna willdevelop novel therapeutics that target an earlier step in the RNAi process.

Company Information

Company Status
Mailing Address
33 Hayden Ave.
Lexington, MA 02421
Email Address
Dicerna (NASDAQ: DRNA) is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes.
Dicerna Pharmaceuticals LinkedIn Company Profile
Social Media
Dicerna Pharmaceuticals Company Twitter Account
Company News
Dicerna Pharmaceuticals News
Dicerna Pharmaceuticals on Facebook
Dicerna Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
Douglas Fambrough
  Douglas Fambrough LinkedIn Profile  Douglas Fambrough Twitter Account  Douglas Fambrough News  Douglas Fambrough on Facebook
Chief Financial Officer
Jack Green
  Jack Green LinkedIn Profile  Jack Green Twitter Account  Jack Green News  Jack Green on Facebook
Chief Medical Officer
Ralf Rosskamp
  Ralf Rosskamp LinkedIn Profile  Ralf Rosskamp Twitter Account  Ralf Rosskamp News  Ralf Rosskamp on Facebook
Chief Scientific Officer
Bob Brown
  Bob Brown LinkedIn Profile  Bob Brown Twitter Account  Bob Brown News  Bob Brown on Facebook
Vice President
Jennifer Lockridge
  Jennifer Lockridge LinkedIn Profile  Jennifer Lockridge Twitter Account  Jennifer Lockridge News  Jennifer Lockridge on Facebook
VP - Bus. Development
James Weissman
  James Weissman LinkedIn Profile  James Weissman Twitter Account  James Weissman News  James Weissman on Facebook
VP - Operations
David Miller
  David Miller LinkedIn Profile  David Miller Twitter Account  David Miller News  David Miller on Facebook



Browse more venture capital transactions:

Prev: 11/14/2007: ChaCha Search venture capital transaction
Next: 11/15/2007: GigaOmniMedia venture capital transaction


Share this article


Where The Data Comes From

We report on every notable VC transaction. VC investment data records on this site are derived from company press releases and news coverage. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary